Latest News

June 18, 2013

ITN Type 1 Diabetes Data to be featured at the American Diabetes Association (ADA) Scientific Sessions

Data from three ITN Type 1 Diabetes trials will be featured during the “Clinical Trials of T Cell Therapeutics for Reversing Type 1 Diabetes” session at the Annual American Diabetes Association (ADA) Scientific Sessions in Chicago, IL. This session will take place on June 22 from 8:00am-10:00am CT.Type 1 Diabetes (T1D) results from T cell mediated destruction of insulin-producing beta cells, and prior preclinical and clinical studies show that therapies targeting T cells can preserve beta cell function.

> read more
June 14, 2013

New Publication: Clinical Outcomes of Remission Induction Therapy for Severe ANCA-Associated Vasculitis

In a manuscript published this week in Arthritis & Rheumatism, Immune Tolerance Network (ITN) investigators sought to better understand the distinction between patients who did and did not achieve the primary endpoint in the RAVE Study (Rituximab for the Treatment of ANCA-Associated Vasculitis and Microscopic Polyangiitis).

> read more
May 17, 2013

ITN Transplant Data to be Presented at American Transplant Congress (ATC) Meeting in Seattle, WA

Sandy Feng, MD, PhD (University of California, San Francisco) will present 5-year follow-up data on tolerant patients from the Immune Tolerance Network’s (ITN’s) WISP-R study, “Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients” next week at the annual American Transplant Congress (ATC) meeting in Seattle, WA.

> read more
May 9, 2013

An Update on Tolerant Kidney Transplant Recipients

A letter published today in the New England Journal of Medicine reports on the long-term outcomes of patients from two ITN-sponsored combined kidney and bone marrow transplantation studies led by David H. Sachs, MD (Massachusetts General Hospital), Tatsuo Kawai, MD, PhD (Massachusetts General Hospital), Megan Sykes, MD (Columbia University) and A. Benedict Cosimi, MD (Massachusetts General Hospital).

> read more
May 7, 2013

New Publication: High-throughput Gene Sequencing to Estimate T cell Populations

The quantification of mature T cell subsets is an important prognostic marker for understanding disease. Killer T cells and Helper T cells, characterized by the expression of cell surface marker proteins CD8 or CD4, respectively, effect different aspects of the adaptive immune system, and the ratio of these two populations can reveal important information about the state of the immune system.

> read more
April 18, 2013

RAVE Study Data Presented at 16th International Vasculitis & ANCA Workshop in Paris

Three abstracts from the ITN’s RAVE study (Rituximab for the Treatment of ANCA-Associated Vasculitis and Microscopic Polyangiitis) led by John Stone, MD (Massachusetts General Hospital) and Ulrich Specks, MD (Mayo Clinic) were presented this week by the RAVE team at the 16th International Vasculitis & ANCA Workshop in Paris, France.

> read more
April 11, 2013

ITN’s TrialShare wins Honorable Mention at Bio-IT World Best Practices Awards

Bio-IT World announced the winners of its Best Practices Awards competition yesterday at its annual meeting in Boston, MA.  Out of the 34 projects evaluated this year, including those from industry giants GlaxoSmithKline, Amgen and Genentech, the Immune Tolerance Network’s (ITN) Clinical Trials Research Portal, TrialShare, received one of only two honorable mentions (see summary of the awards here).

> read more
March 6, 2013

ITN Peanut Allergy Prevention Study Highlighted in the Wall Street Journal

A March 6, 2013 Wall Street Journal article, “Food Allergy Advice for Kids: Don’t Delay Peanuts, Eggs”, discusses the changing landscape surrounding food allergy prevention, citing the Immune Tolerance Network’s (ITN’s) LEAP study as a pivotal effort in determining whether the early introduction of allergenic foods may actually help prevent the development of allergies.

> read more
February 19, 2013

New Publication: ITN’s Type 1 Diabetes Preclinical Consortium’s First Combination Therapy Study

Single-drug approaches to treat type 1 diabetes (T1D) have so far yielded only modest results: just a handful of biologics have been able to transiently delay pancreatic beta cell destruction. As such, creating long-term, sustained improvements in T1D may require multiple agents combined in strategic ways.

> read more
January 24, 2013

Pilot Study Seeks to Understand Biomarkers in Cat Allergy Response

The Immune Tolerance Network (ITN) and Imperial College London are collaborating on a new pilot study examining immunological responses to cat allergen. Allergy to cat dander is one of the most common forms of allergic disease in the US and Europe, and can reduce the quality of life for allergy sufferers. The only form of disease-modifying therapy that does not just treat symptoms is immunotherapy, in which cat allergens are administered over a period of time to desensitize a patient.

> read more